Eloxx Pharmaceuticals Posts $5.54M Q3 Net Loss, Reports $56.3M Cash
Eloxx Pharmaceuticals reported a Q3 2026 net loss of $5.54M, or $0.49 per share, with $56.3M in cash. R&D expenses rose to $4.03M from a prior-year credit of $0.25M. The company dosed the first patients in its Phase 2b Alport syndrome study and received FDA clearance for an ADPKD study. It expects topline Alport study results in mid-2027.
How this was made

The 30-second read
Why it matters
The earnings loss may pressure the stock short‑term, but regulatory clearance and trial initiation could attract long‑term interest.
Market read
Primary micro‑cap earnings release with material regulatory news; relevant for biotech traders.
What to watch
Potential partnership or licensing revenue from exaluren program not disclosed yet.
Background
Eloxx Pharmaceuticals reported Q3 results with a net loss and disclosed progress on two kidney‑disease trials, including FDA clearance for a Phase 2b ADPKD study.
Ticker impact
Q3 2026 earnings release showing a $5.54M net loss and FDA clearance for a Phase 2b ADPKD study.
likely modest downside as market prices in the loss, offset by potential upside from trial progress
Loss is material for a micro‑cap, but FDA clearance is a significant positive development for future valuation.
Market effects
Adds momentum to the kidney‑disease biotech niche as FDA clearances signal regulatory progress.
Limited to US‑listed biotech investors.
Minor; primarily relevant to niche biotech investors.
Counterpoint
The loss may be overstated; focus on cash runway and upcoming trial data could drive a rally.
Key entities
- companyEloxx Pharmaceuticals
US‑listed biotech developing exaluren for kidney diseases.
- regulatorFDA
Granted investigational new drug clearance for Eloxx's ADPKD study.

